Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603291 · ClinicalTrials.gov registry record · Phase 3
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
NCT00603291 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 604 participants.
The verdict
NCT00603291, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.
Interventions
- DRUG Matching Placebo
- DRUG Lorcaserin 10 mg once daily (QD)
- DRUG Lorcaserin 10 mg twice a day (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603291
The ClinicalTrials.gov registry entry for NCT00603291 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT00603291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603291 about?
NCT00603291 is a clinical study titled "BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus". The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.
What is the current status of trial NCT00603291?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2007-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00603291?
The interventions under investigation include: Matching Placebo (DRUG), Lorcaserin 10 mg once daily (QD) (DRUG), Lorcaserin 10 mg twice a day (BID) (DRUG).
Who is sponsoring clinical trial NCT00603291?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.